Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Effects of Aflibercept in AMD
NCT01657669Phase 4Unknown
- Sponsor
- Retina Research Institute
- Start
- Oct 2012
- Primary completion
- Nov 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in age-related macular degeneration (AMD), sponsored by Retina Research Institute. Status: unknown.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01657669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657669.